These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33204024)

  • 1. Metastasis-directed therapy for oligometastasis and beyond.
    Beckham TH; Yang TJ; Gomez D; Tsai CJ
    Br J Cancer; 2021 Jan; 124(1):136-141. PubMed ID: 33204024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Metastasis-Directed Therapy in Genitourinary Cancers.
    Lee KN; Huynh MA
    Curr Treat Options Oncol; 2024 May; 25(5):605-616. PubMed ID: 38573430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
    Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
    Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oligometastatic spectrum in the era of improved detection and modern systemic therapy.
    Katipally RR; Pitroda SP; Juloori A; Chmura SJ; Weichselbaum RR
    Nat Rev Clin Oncol; 2022 Sep; 19(9):585-599. PubMed ID: 35831494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
    Kent CL; McDuff SGR; Salama JK
    Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
    Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
    World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oligometastatic state - separating truth from wishful thinking.
    Palma DA; Salama JK; Lo SS; Senan S; Treasure T; Govindan R; Weichselbaum R
    Nat Rev Clin Oncol; 2014 Sep; 11(9):549-57. PubMed ID: 24958182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes of metastasis-directed treatment using
    Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
    Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
    Kim J; Park JS; Ham WS
    Investig Clin Urol; 2017 Sep; 58(5):307-316. PubMed ID: 28868501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastases-directed local therapies (MDT) beyond genuine oligometastatic disease (OMD): Indications, endpoints and the role of imaging.
    Widder J; Simek IM; Goldner GM; Heilemann G; Ubbels JF
    Clin Transl Radiat Oncol; 2024 Mar; 45():100729. PubMed ID: 38298549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligometastasis and local ablation in the era of systemic targeted and immunotherapy.
    Mazzola R; Jereczek-Fossa BA; Franceschini D; Tubin S; Filippi AR; Tolia M; Lancia A; Minniti G; Corradini S; Arcangeli S; Scorsetti M; Alongi F
    Radiat Oncol; 2020 May; 15(1):92. PubMed ID: 32366258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in local and ablative treatment of oligometastasis in prostate cancer.
    Yao HH; Hong MKh; Corcoran NM; Siva S; Foroudi F
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):308-21. PubMed ID: 25155557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.
    De Bleser E; Tran PT; Ost P
    Curr Opin Urol; 2017 Nov; 27(6):587-595. PubMed ID: 28816714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic radiotherapy in metastatic breast cancer.
    Possanzini M; Greco C
    Breast; 2018 Oct; 41():57-66. PubMed ID: 30007269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligometastasis and oligo-recurrence: more than a mirage.
    Huang F; Wu G; Yang K
    Radiat Oncol; 2014 Oct; 9():230. PubMed ID: 25359216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
    Ost P; Bossi A; Decaestecker K; De Meerleer G; Giannarini G; Karnes RJ; Roach M; Briganti A
    Eur Urol; 2015 May; 67(5):852-63. PubMed ID: 25240974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligometastasis: Past, Present, Future.
    Gutiontov SI; Pitroda SP; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):530-538. PubMed ID: 32976785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
    Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
    World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hormone therapy and chemotherapy in oligometastatic prostate cancer.
    Miura Y; Horie S
    ESMO Open; 2019; 4(Suppl 1):e000471. PubMed ID: 30962966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.